Observational study on ruxolitinib for myelofibrosis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational multicenter study examines patients with primary or secondary myelofibrosis who have started treatment with ruxolitinib as part of their standard care. It aims to assess how clinical and laboratory characteristics influence the long-term survival of these patients. Data will be collected retrospectively and prospectively, including systemic symptoms and splenomegaly assessments, over a minimum observation period of three months and a total study duration of ten years.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Patients diagnosed with Primary Myelofibrosis or secondary to Essential Thrombocythemia/Polycythemia vera who are being treated or have been treated with ruxolitinib therapy in accordance with normal clinical practice.
* Availability of data on clinical history prior to initiation of Ruxolitinib therapy
* Obtaining informed consent for data collection and processing

Exclusion Criteria:

* None

Where it's running

• Azienda Ospedaliera Annunziata
  Cosenza, Calabria, Italy Recruiting
• Grande Ospedale Metropolitano "Bianchi Melacrino Morelli"
  Reggio Calabria, Calabria, Italy Recruiting
• Università degli Studi di Napoli Federico II U.O.C. di Ematologia e Trapianti di midollo
  Naples, Campania, Italy Recruiting
• IRCCS Policlinico Sant'Orsola
  Bologna, Emilia-Romagna, Italy Recruiting
• Università degli studi di Ferrara - Nuovo Polo Ospedaliero di Cona - A.O.U. Arcispedale S. Anna
  Ferrara, Emilia-Romagna, Italy Recruiting
• Azienda Ospedaliero-Universitaria di Parma
  Parma, Emilia-Romagna, Italy Recruiting

Study contacts

• Study coordinator: Francesca Palandri, MD, PhD
• Email: francesca.palandri@unibo.it
• Phone: +390512143044

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• National registry for people with myelofibrosis and anemia in Germany.

  This project will collect health, treatment, and quality-of-life information from people in Germany with primary or secondary myelofibrosis and anemia to see how their care and symptoms change over time.

  Recruiting iOMEDICO AG · Multiple Locations · NCT06976918

• Ruxolitinib given before, during, and after donor stem cell transplant for older adults with myelofibrosis or MDS/MPN overlap

  This phase II test tries whether giving ruxolitinib before, during, and after an allogeneic stem cell transplant helps older adults with myelofibrosis or MDS/MPN overlap have better transplant outcomes and fewer complications like graft-versus-host disease.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07228624

• Combining Momelotinib and Luspatercept for Myelofibrosis Treatment

  This study is testing if combining two medications, momelotinib and luspatercept, can help people with myelofibrosis who need blood transfusions feel better and reduce their transfusion needs.

  Recruiting at 33 sites Phase 2 GlaxoSmithKline · Ann Arbor, Michigan and 32 other locations · NCT06517875

• Adding navtemadlin to ruxolitinib for myelofibrosis patients with poor response

  This study is testing if adding a new drug called navtemadlin to ruxolitinib can help myelofibrosis patients who aren't doing well on ruxolitinib alone.

  Recruiting at 214 sites Phase 3 Kartos Therapeutics, Inc. · Birmingham, Alabama and 214 other locations · NCT06479135

• Evaluating DISC-0974 for treating anemia in myelofibrosis patients

  This study tests if a new treatment called DISC-0974 can help people with myelofibrosis who have anemia feel better and improve their condition.

  Recruiting at 33 sites Phase 1/2 Disc Medicine, Inc · Gilbert, Arizona and 34 other locations · NCT05320198

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.